



## **Paul Vazhayil Thomas**

*Chief Commercial Officer, US*

Paul Vazhayil Thomas is Global Head – Portfolio and Program Management. In this role, he leads the portfolio selection and lifecycle management process in close collaboration with the Commercial, Development, IP/ Legal, Finance and Operations teams to identify, propose and curate Biocon Biologics' product pipeline.



Paul is responsible for recommendations to the DRC on in-licensing and out-licensing of assets, in line with the overall approved portfolio strategy. In addition to managing the Portfolio, he is responsible for managing the approved development programs leading up to their launch in all markets and any function-specific program management activities through the central Program Management Office (PMO).

Paul brings with him over 25 years of international leadership experience in various Program Management, Strategy and Commercial strategy roles at major pharmaceutical players like Pfizer and Wyeth.

He joined Biocon in 2011 and has, since then, taken on positions of increasing responsibility in the organization. Previously as Head of the Monoclonal Antibodies (mAbs) Business Unit, he led the team and successfully secured U.S. FDA approval for the company's first two biosimilar assets, Trastuzumab and Pegfilgrastim. And in his most recent assignment, he was instrumental in laying the foundation for business development and commercial operations in the U.S.

Paul holds an MBA degree from the Wharton School at the University of Pennsylvania, U.S., and a BS in Civil and Environmental Engineering from Cornell University, U.S.